Cargando…

Anakinra for severe forms of COVID-19

Detalles Bibliográficos
Autores principales:	Laine, Marc, Bonello, Laurent
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2020
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413647/ https://www.ncbi.nlm.nih.gov/pubmed/32838318 http://dx.doi.org/10.1016/S2665-9913(20)30272-1

Ejemplares similares

Anakinra for severe forms of COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19
por: Khan, Naim Akhtar
Publicado: (2020)

Anakinra for severe forms of COVID-19 – Authors' reply
por: Hayem, Gilles, et al.
Publicado: (2020)

Effect of anakinra in COVID-19
por: Kooistra, Emma J, et al.
Publicado: (2020)

Effect of anakinra in COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Anakinra for severe forms of COVID-19: a cohort study
por: Huet, Thomas, et al.
Publicado: (2020)

The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH
por: Kavirayani, Akhila, et al.
Publicado: (2020)

Intravenous anakinra for cytokine storm syndromes – Authors' reply
por: Mehta, Puja, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Maoujoud, Omar, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Valette, Xavier, et al.
Publicado: (2020)

Anakinra for patients with COVID-19
por: Martin-Silva, Nicolas, et al.
Publicado: (2020)

Use of anakinra in severe COVID-19: A case report
por: Filocamo, Giovanni, et al.
Publicado: (2020)

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis
por: Dimopoulos, George, et al.
Publicado: (2020)

Heparin-Induced Thrombocytopenia in Severe COVID-19
por: Daviet, Florence, et al.
Publicado: (2020)

Anakinra: a silver lining in COVID-19?
por: Gupta, Rahul
Publicado: (2020)

Anakinra for patients with COVID-19 – Authors' reply
por: Cavalli, Giulio, et al.
Publicado: (2020)

Current evidence on the use of anakinra in COVID-19
por: Khani, Elnaz, et al.
Publicado: (2022)

Could Patients With Inflammatory Bowel Disease Treated With Immunomodulators or Biologics Be at Lower Risk for Severe Forms of COVID-19?
por: Macaluso, Fabio Salvatore, et al.
Publicado: (2021)

Comparison of anakinra and tocilizumab in management of severe COVID-19: a retrospective cohort study
por: KÜÇÜKŞAHİN, Orhan, et al.
Publicado: (2022)

Anakinra in COVID-19: important considerations for clinical trials
por: King, Andrew, et al.
Publicado: (2020)

Anakinra in COVID-19: A step closer to the cure
por: Barkas, Fotios, et al.
Publicado: (2022)

EMA assessing safety of anakinra in adults with COVID-19
Publicado: (2021)

Could anakinra outmatch dexamethasone/tocilizumab in COVID-19?
por: Gupta, Rahul
Publicado: (2022)

Anakinra for the prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease
por: Pontali, Emanuele, et al.
Publicado: (2020)

Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study
por: Bozzi, Giorgio, et al.
Publicado: (2021)

A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID‐19
por: Kharazmi, Amir Behnam, et al.
Publicado: (2021)

To Have and Have Not: Intrinsic Platelet Hyperreactivity?
por: Laine, Marc, et al.
Publicado: (2018)

Mavrilimumab for severe COVID-19
por: Khan, Adil Rashid, et al.
Publicado: (2020)

Mavrilimumab for severe COVID-19
por: Pourhoseingholi, Mohamad Amin, et al.
Publicado: (2020)

Ruxolitinib and Severe COVID-19
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Hypertension and severe COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2023)

Polymorphisms and Severity of COVID-19
por: Sookaromdee, Pathum, et al.
Publicado: (2022)

Cytokine storm and use of anakinra in a patient with COVID-19
por: Nemchand, Priyanka, et al.
Publicado: (2020)

Severe COVID-19 in an Infant with Severe Acute Malnutrition
por: Beniwal, Neetu, et al.
Publicado: (2021)

Interleukin-1 receptor antagonist anakinra in association with remdesivir in severe COVID-19: A case report
por: Franzetti, Marco, et al.
Publicado: (2020)

Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study
por: de la Calle, Cristina, et al.
Publicado: (2021)

Tocilizumab for severe COVID-19 pneumonia
por: Mourad, Jean-Jacques, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Lipworth, Brian J, et al.
Publicado: (2020)

Tocilizumab for severe COVID-19 pneumonia
por: Piano, Salvatore, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p5epvkkmeq2uc44vjc7u8e3s8i